Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-HPβCD in Type 2 Diabetic Kidney Disease
NCT06489340Phase 2Withdrawn
- Sponsor
- ZyVersa Therapeutics, Inc.
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Trappsol Cyclo in diabetic kidney disease (DKD), sponsored by ZyVersa Therapeutics, Inc.. Planned start Jun 2025; status: withdrawn.
02
Drugs
Trappsol Cyclo
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06489340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489340.